Editor’s summary Dravet syndrome (DS) is a severe and difficult-to-treat epileptic syndrome usually caused by a loss-of-function mutation in SCN1A, which encodes the voltage-gated sodium channel 1.1 (NaV1.1), resulting in interneuron inhibitory dysfunction. Here, Mich and colleagues developed a gene replacement therapy for DS that specifically targets these interneurons.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Itay Raphael
T cell receptor precision editing of regulatory T cells for celiac disease
Editor’s summary The primary approach for individuals with celiac disease to manage their symptoms is a strict gluten-free diet, which is both costly and difficult to maintain. Here, Porret et al. report early steps toward another approach to control celiac disease using cell therapy. The authors show that engineered regulatory T cells (eTregs) modified to orthotopically express T cell receptors specific to gluten peptides could quiet gluten-reactive effector T cells in vitro and in vivo.
Disease modification upon 2 weeks of tofacitinib treatment in a mouse model of chronic epilepsy
Editor’s summary Most patients with epilepsy require lifelong medication for seizure management. Hoffman et al. identified Stat3 as a hub gene that regulates transcriptomic changes in the brains of mice after status epilepticus (SE) and in patients with temporal lobe epilepsy. In mice, JAK/STAT signaling was transiently induced during SE and reactivated in the chronic phase weeks after the induction of SE.
The T cell receptor landscape of childhood brain tumors
Editor’s summary There are many types of pediatric brain tumors, but the goal of immunotherapy is shared among them: enabling tumor antigen–specific T cells to kill tumor cells. Here, Raphael et al. report the landscape of T cells among different types of pediatric brain tumors. The authors found that T cell clonality, or the frequency of T cells sharing a T cell receptor (TCR), can inform patient outcomes across tumor types.
BASTA, a simple whole-blood assay for measuring β cell antigen-specific CD4+ T cell responses in type 1 diabetes
Editor’s summary β cell antigen–specific CD4+ T cell responses promote autoimmune destruction of insulin-producing pancreatic β cells. The ability to easily quantify the extent of such responses could potentially benefit the management of patients with or at risk of type 1 diabetes. Lacorcia et al. show that autoreactive CD4+ T cell responses to C-peptide can be accurately measured by detecting secreted IL-2.
NK cells link immune-checkpoint blockade immunotherapy and response in melanoma brain metastases
Natural killer - NK Immune Checkpoint Inhibitor Central Nervous System Cancer Brain metastases (BMs) are the most common intracranial malignancies in adults, affecting 20%–40% of patients with advanced cancer, and markedly outnumbering the incidence of primary brain tumors. Of these, melanoma is one of the tumor types with a high propensity to spread to the brain.
CD200 depletion in glioma enhances antitumor immunity and induces tumor rejection
Abstract High-grade gliomas are a major health challenge with poor prognosis and high morbidity. Immune-checkpoint inhibitors (ICI) have emerged as promising therapeutic options for several malignancies yet show little efficacy against central nervous system (CNS) tumors. CD200 is a newly recognized immune checkpoint that modulates immune homeostasis. CD200 protein is expressed by a variety of cells, including immune cells and stromal cells, and is overexpressed by many tumors.
The Alzheimer’s Disease-Associated Protein BACE1 Modulates T Cell Activation and Th17 Function
Gerard Hernandez-Mir, Itay Raphael, Shankar Revu, Catherine H. Poholek, Lyndsay Avery, William F. Hawse, Lawrence P. Kane and Mandy J. McGeachy J Immunol August 1, 2019, 203 (3) 665-675; DOI: https://doi.org/10.4049/jimmunol.1800363 Key Points BACE1 is expressed in CD4+ T cells and regulates signaling events during activation. BACE1-deficient T cells show reduced IL-17A expression in vitro. BACE1−/− Th17 cells have impaired pathogenicity in EAE.
The Alzheimer's Disease-Associated Protein BACE1 Modulates T Cell Activation and Th17 Function
Gerard Hernandez-Mir, Itay Raphael, Shankar Revu, Catherine H. Poholek, Lyndsay Avery, William F. Hawse, Lawrence P. Kane and Mandy J. McGeachy J Immunol June 17, 2019, ji1800363; DOI: https://doi.org/10.4049/jimmunol.1800363 Key Points BACE1 is expressed in CD4+ T cells and regulates signaling events during activation. BACE1-deficient T cells show reduced IL-17A expression in vitro. BACE1−/− Th17 cells have impaired pathogenicity in EAE.
Identifying biomarkers for monitoring progression of multiple sclerosis
There are currently no reliable methods for assessing the progression of multiple sclerosis (MS) from the relapsing-remitting to the secondary progressive form. This gap in knowledge hinders the ability for therapeutic intervention and ultimately results in continued relapses and physiological deterioration.
A predictive disease-specific protein biomarker fingerprint for clinical relapses and glucocorticoids treatment of multiple sclerosis
Despite extensive research, multiple sclerosis (MS) remains a disease that lacks a definitive prognostic test to predict imminent disease relapses. Thus, patients may undergo years of unnecessary treatments. Additionally, current treatments for MS vary significantly in efficacy between individual patients, and thus there is a critical need to develop biomarkers for treatment efficacy and resistance.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Itay
Contact Itay, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack